Summary of Inventiva FY Conference Call (March 02, 2026) Company Overview - **Company**: Inventiva (NasdaqGM: IVA) - **Focus**: Ongoing phase three NATiV3 trial for NASH (Non-Alcoholic Steatohepatitis) treatment Key Points Industry and Product Insights - **NASH Market**: The NASH market is competitive, with existing players showing modest effect sizes. Inventiva aims to demonstrate a significant improvement in fibrosis and NASH resolution through its drug, lanifibranor [1][2] - **Phase Three NATiV3 Trial**: The trial is designed similarly to the previous NATIVE two trial, focusing on a combined primary endpoint of fibrosis and NASH resolution. The trial excludes F1 patients, potentially providing a competitive advantage [6][9] - **Expected Outcomes**: A target of approximately 20% effect on fibrosis is anticipated, which could significantly disrupt the current market by doubling existing effect sizes [9][10] Clinical Data and Safety - **Previous Trials**: The NATIVE two trial showed a 24% dual endpoint resolution and 18% fibrosis improvement at six months, setting a benchmark for NATiV3 [6][10] - **Safety Concerns**: Previous safety issues related to hepatic events have been addressed, with ongoing monitoring and assessments showing no significant concerns in the current trial [16][21] - **Weight Gain and Tolerability**: In phase IIb, 50% of patients showed no weight gain, while one-third experienced over 5% weight gain. The company emphasizes that treatment efficacy is not dependent on weight gain [26][37] Market Strategy and Commercialization - **Pre-commercialization Efforts**: A chief commercial strategy officer has been appointed to enhance market access and engage with key opinion leaders (KOLs) [73][80] - **Target Population**: The diabetic NASH population is identified as a significant opportunity, with about 70% of NASH patients also having diabetes. The company plans to focus on the full spectrum of F2 and F3 patients, including those with type 2 diabetes [210][217] Future Trials and Regulatory Considerations - **F4 MASH Confirmatory Trial**: Plans for a confirmatory trial in F4 MASH are in place, with the requirement to run an outcome study for full approval. The trial is expected to start around the time of the NDA filing in 2027 [94][104] - **Patient Selection**: The strategy involves enrolling patients with significant portal hypertension to ensure a higher event rate, which is crucial for powering the trial [135][144] Financial Position - **Cash Position**: As of the end of 2025, the company has EUR 231 million in cash, projected to last through Q3 2027, assuming positive trial data. A EUR 149 million raise was completed in November 2025 [195][196] Combination Therapies - **Potential for Combination**: Lanifibranor's unique mechanism allows for potential combination therapies, particularly with GLP-1s for diabetes management and cardiovascular risk reduction [197][205] Additional Insights - **Market Dynamics**: The company acknowledges the evolving landscape of combination therapies in the NASH space and is open to exploring these opportunities as data becomes available [197][205] - **Investor Communication**: The company aims to provide clear guidance on trial data and market strategies as they progress through the year [39][56] This summary encapsulates the key discussions and insights from the Inventiva FY Conference Call, highlighting the company's strategic direction, clinical trial progress, and market positioning in the NASH treatment landscape.

Summary of GSK Conference Call Company Overview - **Company**: GSK (GlaxoSmithKline) - **Focus**: Research and Development (R&D) strategy, particularly in oncology, respiratory diseases, HIV, and infectious diseases Key Points R&D Strategy - GSK's R&D strategy emphasizes the science of the immune system and the application of technologies, focusing on both organic and inorganic growth opportunities [4][5] - The company has transitioned into marketed assets, with a focus on "bolt-on deals" to enhance its portfolio [5] - A clear lens on capital allocation is maintained, comparing internal and external opportunities to optimize R&D investments [6] Oncology Focus - GSK is concentrating on oncology, with notable assets like momelotinib and the B7H3 and B7H4 ADCs [7][8] - The strategy involves pivoting towards assets with apparent efficacy in monotherapy during phase one trials, avoiding the complexities of combination therapies [8] - Significant data capabilities have been built through collaborations and acquisitions, enhancing decision-making for external acquisitions [9][10] Respiratory Disease Developments - GSK is well-positioned in lung disease, particularly with Nucala for COPD, targeting a market of 300 million individuals [12][13] - The company is advancing long-acting monoclonal therapies and has pivotal studies planned for 2027-2028 [13] - There is a focus on addressing fibrosis in liver, kidney, and lung tissues, with ongoing studies in these areas [14] HIV and Infectious Diseases - GSK is developing long-acting treatments for HIV, with a focus on Q4M regimens expected to launch in 2028 [26][27] - The company is addressing the challenges posed by generic competition in the HIV market, particularly with the impending loss of exclusivity for Dolutegravir [25][26] - In infectious diseases, GSK is focusing on hepatitis B and vaccine innovations, with significant data expected by the end of the year [15] Pipeline and Portfolio Management - GSK's pipeline is characterized by a focus on major blockbusters, with a rigorous culling of non-promising assets [17] - The company has achieved 13 successful phase three studies last year, indicating strong operational capabilities [18] - Upcoming catalysts include bepirovirsen for chronic hepatitis B and Canlapixent for respiratory conditions, with significant market potential [19][20] Decision-Making in Acquisitions - GSK's acquisition strategy is driven by the need for effective clinical outcomes and scalability, as seen in the EFI deal for fibrosis treatment [30][31] - The company prioritizes assets that can integrate well into existing studies and have favorable manufacturing profiles [32] Budget and Resource Allocation - GSK's R&D budget is optimized to ensure that any new assets must justify their inclusion by providing significant value [33][34] - The focus remains on enhancing R&D effectiveness through technology and strategic investments [34] Additional Insights - GSK's approach to R&D is characterized by a blend of internal development and strategic acquisitions, aiming to create a robust pipeline that addresses significant medical needs [17][18] - The company is actively working to dispel perceptions of a weak pipeline by highlighting the strategic rationale behind its asset selection and development focus [16]